Esketamine nasal spray for treatment-resistant depression
Treatments studied
Part of Mental health clinical trials.
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with major depression, either a single episode lasting at least 12 months or repeated episodes, starting before age 55.
- You have tried at least two different oral antidepressants for your current depression and they did not work well (less than 25% improvement).
- Your current depression and treatment history must be confirmed by a doctor’s review.
- You are comfortable giving yourself the nasal spray and can follow the instructions.
- If you can become pregnant, you must have negative pregnancy tests before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if intravenous ketamine can help people with treatment-resistant depression who haven't found relief from at least two other treatments. If you qualify, you'll receive ketamine infusions to see if it improves your mood.
This study tests combining a specific type of therapy (BCBT-SP) with esketamine nasal spray to help people with treatment-resistant depression who are having ongoing suicidal thoughts. The goal is to see if this combination can reduce suicidal ideation more effectively than either treatment alone.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This study tests esketamine nasal spray (a fast-acting antidepressant) for people with treatment-resistant depression who haven't gotten better after trying at least two other antidepressants. It looks at how well the spray works in everyday doctor's offices, not just in research clinics.
This study tests whether a nasal spray (esketamine) is more effective than aripiprazole (an oral medication) for treating depression in adults aged 60-74 who haven't responded to at least three previous antidepressants. The goal is to see which option helps better when standard treatments haven't worked.
This trial compares two forms of ketamine—given by IV or as a nasal spray—in people with major depression that hasn't improved after trying at least two other antidepressants. The goal is to see which treatment works better.
Hear when a new Depressive Disorder, Treatment-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.